Top-News
Gesundheitswesen USA

Quest Diagnostics News

Aktie
WKN:  904533 ISIN:  US74834L1008 US-Symbol:  DGX
128,05 €
+0,95 €
+0,75%
21:14:13 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
112,44 Mio.
Marktkapitalisierung *
14,24 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
S&P 500
IR-Website
zur Website
*Stand: 08.11.2023
Weiter aufwärts? Long handeln - Jetzt mit Hebel 6,77: ME92D5

Quest Diagnostics News

07.05.24 - PR Newswire
Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads Conference
Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads Conference PR Newswire
06.05.24 - PR Newswire
Quest Diagnostics Names Murali Balakumar Senior Vice President and Chief Information and Digital Officer
Quest Diagnostics Names Murali Balakumar Senior Vice President and Chief Information and Digital Officer PR Newswire
01.05.24 - PR Newswire
Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI
Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI PR Newswire
23.04.24 - PR Newswire
Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024 PR Newswire
22.04.24 - PR Newswire
Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease PR Newswire
02.04.24 - PR Newswire
Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay
Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-​Line Genetic Test for Developmental Delay PR Newswire
26.03.24 - PR Newswire
Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease PR Newswire
19.03.24 - PR Newswire
Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024
Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024 PR Newswire
23.02.24 - PR Newswire
Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference
Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference PR Newswire
21.02.24 - PR Newswire
Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery
Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery PR Newswire
15.02.24 - PR Newswire
Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection
Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection PR Newswire
13.02.24 - PR Newswire
Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery
Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery PR Newswire
12.02.24 - PR Newswire
First PFAS "Forever Chemicals" Consumer-Initiated Blood Test with Physician Consult Launches on questhealth.com
First PFAS "Forever Chemicals" Consumer-​Initiated Blood Test with Physician Consult Launches on questhealth.com PR Newswire
08.02.24 - BNP Paribas
Quest Diagnostics – Gedämpfte Gewinnperspektiven halten Aktie auf Talfahrt
Der US-​Anbieter von diagnostischen Tests bekommt den Kollaps des Corona-​Geschäfts zu spüren. Vorstandschef Jim Davis konnte Investoren mit der Prognose nicht überzeugen.
08.02.24 - BNP Paribas
Quest Diagnostics – Gedämpfte Gewinnperspektiven halten Aktie auf Talfahrt
Der US-​Anbieter von diagnostischen Tests bekommt den Kollaps des Corona-​Geschäfts zu spüren. Vorstandschef Jim Davis konnte Investoren mit der Prognose nicht überzeugen.
01.02.24 - PR Newswire
Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share PR ...
31.01.24 - PR Newswire
Ten Years Running: FORTUNE Names Quest Diagnostics one of 2024 "World's Most Admired Companies"
Ten Years Running: FORTUNE Names Quest Diagnostics one of 2024 "World's Most Admired Companies" PR Newswire
22.01.24 - PR Newswire
Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus' TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma
Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus' TLR9 agonist in hepatocellular ...
17.01.24 - PR Newswire
Quest Diagnostics to Release Fourth Quarter and Full Year 2023 Financial Results on February 1, 2024
Quest Diagnostics to Release Fourth Quarter and Full Year 2023 Financial Results on February 1, 2024 PR Newswire
17.01.24 - PR Newswire
Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health
Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health PR Newswire

Newssuche

Videos

07.05.24 +17,87%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »